AI assistant
Gossamer Bio, Inc. — Director's Dealing 2020
Feb 19, 2020
32603_dirs_2020-02-19_bc1dc2ea-32b8-40d4-8893-eba3c673eb4a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Gossamer Bio, Inc. (GOSS)
CIK: 0001728117
Period of Report: 2020-02-14
Reporting Person: Dupont Jakob (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-14 | Common Stock | A | 46500 | $0.00 | Acquired | 46500 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-14 | Stock Option (right to buy) | $14.55 | A | 71500 | Acquired | 2030-02-14 | Common Stock (71500) | Direct |
Footnotes
F1: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date.
F2: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.